DRI Healthcare Trust Asset Resilience Ratio
DRI Healthcare Trust asset resilience ratio. DRI Healthcare Trust (DHT-U) has an Asset Resilience Ratio of 13.91% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DHT-U days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of DRI Healthcare Trust (None–None)
Asset resilience ratio of DRI Healthcare Trust from None to None. This chart shows how DRI Healthcare Trust's Asset Resilience Ratio has changed over time. Read DRI Healthcare Trust balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down DRI Healthcare Trust's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see DHT-U total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $125.67 Million | 13.91% |
| Total Liquid Assets | $125.67 Million | 13.91% |
Asset Resilience Insights
- Moderate Liquidity: DRI Healthcare Trust has 13.91% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
DRI Healthcare Trust Industry Peers by Asset Resilience Ratio
Compare DRI Healthcare Trust's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
DRI Healthcare Trust Asset Resilience Ratio by Year (None–None)
DRI Healthcare Trust asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for DRI Healthcare Trust.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About DRI Healthcare Trust
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.